Compugen
- Country
- Ownership
- -
- Employees
- 68
- Market Cap
- -
- Introduction
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
- Conditions
- Ovarian CancerOvarian Cancer Recurrent
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06888921
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies
- Conditions
- NeoplasmCancer, Malignant Tumors
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06759649
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸NEXT Oncology San Antonio, San Antonio, Texas, United States
🇺🇸START, San Antonio, Texas, United States
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
- Conditions
- Endometrial NeoplasmsSolid TumorOvarian CancerHead and Neck Cancer
- Interventions
- Drug: COM701 in combination with BMS-986207 and nivolumab.
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT04570839
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Johns Hopkins University Oncology Center., Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
- Conditions
- HNSCCMSS-CRCAdvanced CancerLung CancerOvarian CancerColon CancerMultiple MyelomaMicrosatellite Stable Colorectal CarcinomaPlasma Cell Neoplasm
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT04354246
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸START Midwest., Grand Rapids, Michigan, United States
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
- Conditions
- Advanced CancerOvarian CancerBreast CancerLung CancerEndometrial CancerOvarian NeoplasmTriple Negative Breast CancerLung NeoplasmNeoplasm MalignantColo-rectal Cancer
- Interventions
- Drug: COM701 with Opdivo (Nivolumab).
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 121
- Registration Number
- NCT03667716
- Locations
- 🇺🇸
University of California Los Angeles (UCLA)., Los Angeles, California, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States